Post-marketing clinical study of rituximab monotherapy at eight weekly infusions in relapsed or refractory patients with indolent B-cell non-Hodgkin's lymphoma.

Trial Profile

Post-marketing clinical study of rituximab monotherapy at eight weekly infusions in relapsed or refractory patients with indolent B-cell non-Hodgkin's lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2010

At a glance

  • Drugs Rituximab (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; MALT lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Sponsors Zenyaku Kogyo
  • Most Recent Events

    • 15 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top